Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Photocure ASA ( (PHCUF) ) has issued an announcement.
Photocure ASA has scheduled the release of its fourth quarter and preliminary full-year 2025 financial results for 18 February 2026, with the report and presentation set to be published early that morning on the company’s website. Later that day, management will host a live English-language webcast presentation for investors, led by CEO Dan Schneider and CFO Erik Dahl, offering real-time Q&A and signaling continued emphasis on transparency and engagement with the market.
The webcast, which will run from 14:00 to 14:45 CET and be accessible through a dedicated streaming link, is expected to draw interest from shareholders and analysts tracking the company’s performance in bladder cancer diagnostics. By framing the event as an interactive investor presentation, Photocure underscores its efforts to maintain visibility in the capital markets and to keep stakeholders closely informed about its financial trajectory and operational progress.
More about Photocure ASA
Photocure ASA, branded as The Bladder Cancer Company, operates in the healthcare and medical technology sector, focusing on diagnostic and therapeutic solutions for bladder cancer. Its proprietary imaging technology makes cancer cells glow bright pink during procedures, supporting improved detection and outcomes for patients. The company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker PHO, with products marketed globally via platforms such as cysview.com.
Average Trading Volume: 49,982
Current Market Cap: NOK1.74B
Find detailed analytics on PHCUF stock on TipRanks’ Stock Analysis page.